World Monitor Magazine WM_November_2019_web | Page 44

EXPERT OPINION
The number of new product launches has been steadily increasing
and most are now specialty drugs
Average annual New Active Substance launches and characteristics
Specialty 38%
Orphan 34%
25%
17%
Biologic
Oncology
50%
37%
25%
23%
61% 65%
44%
29%
25% 35%
30%
45%
54
46
33
2004-2008
NAS = new active substance
36
2009-2013
2014-2018
Average Annual Global NAS Launches
2019-2023
Forecast
Source: IQVIA Institute, Dec 2018
Notes: Percentages do not sum due to overlap in molecule types. There are 503 rare disease in the pipeline V22 Modeling Inputs 012419
. IQVIA Russia Customer Meeting 091719
what impact do these innovations
have on the process of forming the
cost of drugs and patients' access to
effective medicines?
I already spoke about this earlier in
the framework of the issue of costs
for the healthcare system. It can
be an incentive for market growth,
provides maximum transparency and
structuring – one can distribute the
money according to certain principles,
management will become effective. In
turn, there will be some cash saving,
and the government can invest reserves
further. Such an approach in healthcare
helps to expand the list of services, and
it will not be necessary to go abroad
for some inaccessible treatment in
Kazakhstan, where the services will
become better, the level of doctors
will grow further and, accordingly, the
social status of becoming a doctor will
become more attractive. Also, it will
also be attractive for business to bring
42
world monitor
innovative treatment to the country,
because there will be a worthy place to
apply it.
Recently, your company completed
the acquisition of Shire and a merger
of assets, which allowed Takeda to
enter the 20 largest pharmaceutical
companies in the world. Should we
expect the arrival of new products
on the Kazakhstani market and in
what technologies should we expect
a breakthrough from your company?
Yes, I talked about the history of the
company, that the deal with Shire was
the largest acquisition in the industry.
We entered TOP-20 on the world stage,
and in Kazakhstan, we are among TOP-3.
We reviewed the strategy and priorities,
our key therapeutic areas, not forgetting,
of course, about the local needs of our
patients. We are increasingly turning our
attention to blood diseases, immunology,
oncology of various organs, including
lung cancer, and rare diseases. We are
developing a vaccine business globally,
and a manufacturing site was recently
opened to produce a vaccine against
Dengue fever in Singen, Germany. A
vaccine against the Zika virus is also
under development.
In Kazakhstan and Central Asia, we
are preparing to introduce innovative
treatments in immunology, in particular,
hereditary angioedema (HAE), multiple
myeloma, Hodgkin's lymphoma, inhibitory
hemophilia and non-small cells lung
cancer. We will continue to work on
rare diseases – Hunter syndrome and
Fabry disease. Besides, we will devote
special attention to programmes of
social responsibility and sustainable
development. Over the next few years,
Takeda in Kazakhstan, Central Asia and
the Caucasus will be a market leader, a
trusted partner of the state and a provider
of innovative treatment methods to meet
the needs of patients in this region.
14